Articles - GLP1 drugs changing weight loss and Life & Health insurance


Weight-loss injectables like Wegovy or Ozempic are gaining popularity amid an escalating global obesity crisis. Since 1975, worldwide obesity rates have nearly tripled, with projections indicating that over half of the global population will be overweight or obese by 2035. John Schoonbee, Global Chief Medical Officer, and Adam Strange, Life & Health R&D Manager, elaborate on the impact of GLP-1 drugs on weight loss, metabolic health and insurance. These medications influence risk factors such as insulin resistance, cardiovascular disease, and cancer. Additionally, they discuss the implications of these drugs on Life & Health insurance, including life, critical illness, and disability income, as well as future underwriting risk assessments.

 

Back to Index


Similar News to this Story

Stars of the Future 2026 Edition of Actuarial Post Magazine
Our Stars of the Future 2026 take center stage in the magazine this month. We would like to congratulate our overall winner Olauria Mafura from Royal
PHP - a race across the world
A few weeks ago, only a relatively select group of people knew what PHP: Hypertext Pre-processor (PHP) is. Most were software engineers and web develo
AI and the future of compensation: Pricing value
AI is changing what work is worth faster than job titles change. Compensation leaders need to shift from pricing jobs to pricing capabilities: Rewardi

Site Search

Exact   Any  

Latest Actuarial Jobs

Actuarial Login

Email
Password
 Jobseeker    Client
Reminder Logon

APA Sponsors

Actuarial Jobs & News Feeds

Jobs RSS News RSS

WikiActuary

Be the first to contribute to our definitive actuarial reference forum. Built by actuaries for actuaries.